BFRI News and Press, Biofrontera Inc. From 03/08/24

WOBURN, MA / ACCESSWIRE / March 8, 2024 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2023 on Friday, March 15, 2...

2024-03-05 07:46:44 ET More on Medicus Pharma Ltd. Historical earnings data for Medicus Pharma Ltd. Financial information for Medicus Pharma Ltd. Read the full article on Seeking Alpha For further details see: Medicus Pharma appoints Erica Monaco as COO

Biofrontera (NASDAQ: BFRI) , a biopharmaceutical company specializing in the commercialization of dermatologic products, has closed on a securities purchase agreement. According to the announcement, the agreement is with healthcare-focused institutional investors led by Rosalind Advisors. The fin...

Company closed financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities and...

2024-02-21 10:00:32 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...

2024-02-21 08:34:43 ET Losers: Pop Culture Group Co Ltd ( CPOP ) -33% . Shineco ( SISI ) -27% . Palo Alto Networks PANW -24% after Q2 earnings release . Biofrontera ( BFRI ) -23% . Amplitude AMPL -22% after Q4 earnings release . ...

2024-02-20 09:56:22 ET More on Biofrontera Seeking Alpha’s Quant Rating on Biofrontera Historical earnings data for Biofrontera Financial information for Biofrontera Read the full article on Seeking Alpha For further details see: Biofronter...

Ameluz ® transfer price to Biofrontera AG reduced significantly Control of all US clinical trials of Ameluz transfers to Biofrontera Inc. on June 1 WOBURN, MA / ACCESSWIRE / February 20, 2024 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company") , a biopharmaceutical...

Company secures financing of $8.0 million with an additional $8.0 million second tranche tied to milestones for aggregate proceeds of $16 million gross priced at market per Nasdaq rules Funding and recent restructuring of supply agreement allow Biofrontera Inc to assume R&D activities an...

FDA has set a target action date of October 4, 2024 sNDA supported by two Phase 1 safety studies 1 Aims at actinic keratosis (AK) field treatment with up to 3 tubes An estimated 13 million treatments given each year for AK in the US 2 WOBURN, MA / ACCESSWIRE / February 5, 2024 /...